glp 1 inhibitor drugs Dosage of GLP-1 analogues GLP-1 Drugs: Where We Are

Issue 42 of The Altascientist explores GLP-1 receptor agonist drug development, covering preclinical models, bioanalytical assays, clinical study design, and manufacturing

Yale Medicine experts explain who qualifies, who can prescribe, and what to expect.

Glucagon-like peptide 1 (GLP1) receptor agonists reduce the rate of major adverse cardiovascular events in people with type 2 diabetes mellitus

Evidence-based insights for patients and providers.

They enhance insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety

Some people who take GLP-1 drugs such as semaglutide and tirzepatide see little to no changes to their weight